Know Cancer’s Next Move
How do you guide treatment decisions when next steps are unclear?
Signatera™ Molecular Residual Disease (MRD) Assay is a highly sensitive and custom designed test, using circulating tumor DNA (ctDNA) to help inform treatment decisions.
Informing treatment decisions along the continuum of care
Use Signatera™ after surgery to evaluate the need for adjuvant chemotherapy.
Use Signatera™ alongside CEA and imaging to detect recurrence earlier.
Assess a patient’s response to treatment in the neoadjuvant, adjuvant or immunotherapy settings.
Identify high risk patients with progressive disease who may benefit from earlier intervention or additional imaging.
Clinical applications of ctDNA testing
ALTAIR: compelling evidence on the value of treating on molecular recurrence (TOMR)
As the randomized, doublet-blind, phase III study arm, ALTAIR sets out to evaluate the efficacy and safety of preemptive treatment with TAS-102 (Lonsurf; combination of trifluridine and tipiracil hydrochloride), compared to placebo.
Treating patients when they recur at a molecular level, rather than waiting for radiographic evidence of disease, may give clinicians a better chance of clearing patients of their disease and potentially improving clinical outcomes.
Interested in learning more about the results of the ALTAIR read out?
What is the significance of the data from ASCO GI?
The presence of post-surgical ctDNA has been shown to be the most significant prognostic factor and reinforces the predictive value of adjuvant chemotherapy (ACT).
- ESMO 2023: ctDNA positive patients who received ACT had significantly higher DFS at 24 months compared to those with no ACT (38.6% v. 16.1%, p-value <0.01)
- ASCO GI 2024: ctDNA positive pts with sustained ctDNA clearance after ACT were significantly associated with >90% DFS. For patients with transient clearance who ultimately recurred clinically or radiographically, 98% experienced molecular recurrence by 18 months
- By analyzing the duration of clearance, we validate the power of serial testing: patients who clear their ctDNA has been shown to be a strong indicator of disease-free survival (DFS)
Fine tuning chemotherapy
As we have seen in the recently presented data, patients who do not clear their ctDNA are at an increased risk of recurrence. Listen in how one providers incorporates Signatera™ into to his practice with the goal to impact patient care.
Tracks Disease Burden Over Time via ctDNA Dynamics
- Signatera™ is designed to accurately detect residual disease with an ultra-low level of detection (0.01% MTM/mL)
- Real time ctDNA analysis can help inform important adjuvant therapy decisions
- Signatera™ can also track ctDNA dynamics so you can gain real-time insight of disease burden.
Facilitating shared-decision making
Listen in to Keith’s incredible story about how he and his provider used Signatera™ to help inform next steps in his treatment journey.
Is Signatera right for your patients?
We’re here to help you find out
References
1Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019.
2Coombes RC, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019;25(14):4255-4263.
3Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.
4Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019;37(18):1547-1557.
5Kotani D. et al., Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer, Nature Medicine v29 Issue 1 Jan 2023